



Press Release

FOR IMMEDIATE RELEASE

German biotech company Cilian appoints new CEO

Münster, Germany, January 28th, 2011 – Cilian AG, a privately held biotech company leveraging a unique and revolutionary expression system to produce recombinant proteins and therapeutic enzymes with an eukaryotic single cell organisms, is announcing that it has appointed Christian Scheiner as new Chief Executive Officer. Christian Scheiner will succeed Remco Brandt as CEO as from February 1st, 2011.

In concert with the founder of Cilian, Dr. Marcus Hartmann, the inventor of and brain trust behind CIPEX (Ciliate based proprietary expression technology), Christian Scheiner will be responsible for the management and strategic direction of the company. He brings to Cilian more than 25 years of management experience in the international pharmaceutical industry with Boehringer Ingelheim, STADA Pharmaceuticals and The Forty To See.

Remco Brandt, M.Sc., who has been fully supportive of the change in control has decided to step down as CEO but will support the company as a consultant.

Christian Scheiner, CEO of Cilian comments: "CIPEX is a unique and innovative technology for the expression of therapeutic proteins and enzymes. It has proven to address several deficiencies with conventional expression systems currently used in the biotech field. CIPEX offers significant improvement in the areas of safety, handling, yield and glycosylation profile while being competitive and cost effective. Cilian will continue to create and enhance value for its current major pharma collaboration partner, seek to expand use of CIPEX with additional collaborations and explore possibilities for a large strategic transaction."

Sebastian Schneberger, chairman of the supervisory board of Cilian AG said: "I would like to thank Remco Brandt for his dedication and professional contribution to Cilian AG during the last 6 years. He has played a pivotal role



in transitioning the business model from a platform technology towards products and services. His advice, experience and visionary strengths have been invaluable to the Company and have strongly supported a successful establishment of Cilian AG.”

About Cilian AG

Founded in 2001 by its Chief Scientific Officer, Dr. Marcus Hartmann, Cilian is an emerging biotechnology company developing and marketing a novel protein expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins particularly antibodies, therapeutic vaccines and enzymes. While Ciliates secrete therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce therapeutic proteins that are safe, effective and cost competitive, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

For more information:

Cilian AG:

www.cilian.de

Marcus Hartmann, Ph.D. (CSO)

Phone: +49 (0) 251 6 20 310